NEW DELHI, September 17, 2022 (Globe Newswire) — The Global Point of Care (POC) Infectious Disease Testing Market is booming primarily due to the rapidly growing demand for PoC test kits for the diagnosis of the increasing prevalence of infectious diseases such as HIV. Influenza, RSV, and Covid, among the world’s population.
Bluewave ConsultingA leading strategic consulting and market research firm, in its recent study, estimated the size of the Global Point of Care (POC) Infectious Disease Testing Market At USD 1.4 billion in 2021. BlueWeave expects the global point of care (PoC) infectious disease testing market to grow at an impressive CAGR of 17.4% between 2022 and 2028 to reach a size of USD 4.22 billion by 2028. Major growth factors for the market expansion include the increasing number of people affected by various infectious diseases like HIV, COVID, Influenza and RSV across the globe.
Global Point of Care (POC) Infectious Disease Testing Market – Technology Advancements
Due to the strong product portfolio and impressive distribution network of large corporations in developed and developing countries, the market for infectious disease diagnostics is semi-consolidated. Strategic tie-ups between the key players in this sector and the launch of diagnostic products are anticipated to fuel the growth of the companies and increase their market share. However, the potential market potential is allowing many domestic competitors to enter in the coming years. This will result in a slightly fragmented market by 2028. For example, Precipio Inc. and ADS Biotech joined a strategic alliance in July 2020 to develop a COVID-19 detection test based on lateral flow immunoassay. It gained EUA approval to distribute the kit to physician’s laboratories, retail pharmacies and direct-to-consumer.
Request for Sample Report @ https://www.blueweaveconsulting.com/report/point-of-care-infectious-disease-testing-market/report-sample
Global Point of Care (POC) Infectious Disease Testing Market – Growing Demand
The prevalence of infectious diseases, including HIV, influenza and RSV, is increasing globally, further increasing the rate of diagnosis of patients. For example, the United Nations Program on HIV/AIDS (UNAIDS) estimated that 38 million people worldwide received an HIV/AIDS diagnosis in 2019. Additionally, a research study released by the World Health Organization (WHO) estimated that around 10 million individuals worldwide were infected with tuberculosis in 2018. Consequently, during the period of analysis, the increasing prevalence of infectious diseases will increase the need for POC devices for their diagnosis and, in turn, support the expansion of the market.
Global Point of Care (POC) Infectious Disease Testing Market – By Technology
The technology-driven Global Point of Care (POC) Infectious Disease Testing market has segments such as Agglutination Tests, Flow-through Tests/Immuno-concentration Assays, Molecular Diagnostics and other segments. In 2020, the lateral flow immunoassay market category represented a one-sided market share. Quick diagnostics and accessibility of test kits in decentralized settings is responsible for supremacy. Additionally, the segment has grown as a result of more products being launched as a result of COVID-19.
The increasing use of innovative tests such as RT-PCR and ELISA in infectious disease POC test kits is expected to drive the molecular diagnostics market by 2028. Additionally, the increase in FDA approvals is probably going to accelerate the segment’s revenue growth. Additionally, the flow-through test/immunoconcentration assay market is anticipated to expand at a large CAGR during the forecast period as more industry participants work to introduce sophisticated kits based on flow-through technology in the international market. Furthermore, throughout the analysis period, the agglutination test segment is expected to grow further due to increasing knowledge about the use of agglutination tests for the diagnosis of infectious diseases.
North America dominates the PoC infectious disease testing market, with the US having the highest revenue share, largely due to factors such as the existence of large companies and a well-established healthcare system. In addition, the expected revenue share is supported by the introduction of technology advancements in the US. Meanwhile, Asia Pacific (APAC) is expected to expand at the fastest rate, driven by increased R&D investments in patient-focused institutions in Japan and China. In addition, variables that are expected to drive regional success include the rapidly increasing burden of chronic infectious diseases and the existence of government initiatives to encourage early detection. Businesses in APAC are focusing on manufacturing novel assays. For example, in May 2017, One BioMed and Singapore’s A*STAR’s Genome Institute established a joint laboratory venture to manufacture molecular diagnostic assays. The goal of this collaboration is to develop the assay for the Asian market for clinical infectious disease diagnosis. Among these tests are tests for juvenile respiratory infections, diseases transmitted by mosquitoes, and drug-resistant tuberculosis.
Impact of COVID-19 on the Global Point of Care (PoC) Infectious Disease Testing Market
The COVID-19 pandemic had a minor impact on pharmaceutical firms and research organizations were focusing on manufacturing POC kits for COVID-19 diagnosis. The launch of state-of-the-art kits with fast turnaround time will accelerate the market expansion during the period of analysis. For example, BD (Becton, Dickinson, and Company) reported in July 2020 that the USFDA has approved the use of Emergency Use Authorization (EUA) to provide a quick, point-of-care SARS- CoV-2 diagnostic test can be done. Its widely used BD Veriter Plus system. However, due to supply chain disruptions and implementation of lockdown measures, demand and sales of diagnostic products related to infectious diseases, such as MRSA (methicillin-resistant Staphylococcus aureus), HIV (Human Immunodeficiency Virus), and CDI (Clostridium difficile infection) are low. are gone. Additionally, a reduction in routine testing of diagnostic procedures for various disorders has impacted revenue for companies including Roche and Abbott. However, the market is expected to bounce back sharply in the post-COVID-19 pandemic period.
Allere, Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd., Siemens Healthniers, BD & Co., Chembio Diagnostics Inc., Trinity Biotech, Cardinal Health, Quest Diagnostics Inc., Bio-Rad Labs Inc., Biomerix SA, Sight Diagnostics Ltd., Jean POC, Trivitron Healthcare, OJ -Bio Ltd., and Ortho-Clinical Diagnostics are the leaders in the Global Point of Care (POC) infectious disease testing market. Key players are currently forming strategic alliances with other well established and emerging organizations. The partnership aims to strengthen its market presence by creating a strong product portfolio that supports accurate diagnosis.
- Chembio Diagnostics, Inc., released the accelerated PoC COVID-19/Flu A&B test in April 2021. Test results are available in 15 minutes. Roche launched the Cobas SARS-CoV-2 Variant Set 1 test in March 2021. This test is designed to find the COVID-19 variations that are present in the UK, South Africa and Brazil.
scope of report
|year is considered||Historical Data – 2018–2021|
|Base Year – 2021|
|Estimated Year – 2022|
|Forecast – 2022–2028|
|facts covered||Revenue in million USD|
|market coverage||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|product/service segmentation||By technique, by disease, by end use, by region|
|Key Players||Thermo Fisher Scientific Inc., Allere Inc., Calypt Biomedical Corporation, Chembio Diagnostic Systems, Inc., Meridian Bioscience, Inc., Medmira, Inc., Trinity Biotech PLC, Sekisui Diagnostics, OraSure Technologies, Inc., and Quidl Corporation.|
- lateral flow
- agglutination assays
- flow-through test
- molecular diagnostics
- HIV POC
- Clostridium difficile POC
- HBV PoC
- Infections involving pneumonia or streptococcus
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu PoC
- HCV POC
- MRSA POC
- TB and drug resistant TB POC
- HSV (herpes simplex virus) POC
by end use
- Assisted Living Healthcare Facilities
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Please find some new reports below:
BlueWeave Consulting provides comprehensive Market Intelligence (MI) solutions to businesses regarding various products and services online and offline. We provide all inclusive market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BWC has built its reputation by providing quality inputs and nurturing long lasting relationships with its clients. We are one of the promising Digital Mi Solutions companies that provide agile support to make your business endeavors a success.
Bluewave Consulting & Research Pvt. Ltd.
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662